23andMe Overview
Latest Deal Type
2ndary - Private
23andMe General Information
Description
Operator of a consumer genetics and research platform designed to help people access, understand and benefit from the human genome. The company's consumer genetics and research platform provide web-based interactive tools for individuals to learn and explore their own genetic information through DNA analysis technologies, enabling patients to gain deeper insights into personal ancestry, genealogy and inherited traits.
23andMe Timeline
Want to dig into this profile?
We’ll help you find what you need
Learn more
23andMe Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 17. Secondary Transaction - Private |
01-May-2019 |
|
00000 |
|
Completed |
Generating Revenue |
| 16. Later Stage VC |
31-Mar-2019 |
|
00000 |
|
Completed |
Generating Revenue |
| 15. Secondary Transaction - Private |
01-Jan-2019 |
|
00000 |
|
Completed |
Generating Revenue |
| 14. Secondary Transaction - Private |
03-Dec-2018 |
|
00000 |
|
Completed |
Generating Revenue |
| 13. Later Stage VC |
23-Jul-2018 |
00000 |
00000 |
00.00 |
Completed |
Generating Revenue |
| 12. Later Stage VC |
01-Jan-2018 |
|
00000 |
|
Completed |
Generating Revenue |
| 11. Secondary Transaction - Private |
22-Dec-2017 |
|
00000 |
|
Completed |
Generating Revenue |
| 10. Later Stage VC (Series F) |
11-Sep-2017 |
00000 |
00000 |
00.000 |
Completed |
Generating Revenue |
| 9. Later Stage VC |
|
$1.32M |
$242M |
|
Completed |
Generating Revenue |
| 8. Grant |
13-Oct-2016 |
$1.7M |
$241M |
|
Completed |
Generating Revenue |
23andMe Cap Table
To view 23andMe‘s complete cap table, request access >>
| Stock |
# of Shares
Authorized |
Par Value |
Dividend Rate ($) |
Original
Issue Price |
Liquidation |
Liquidation
Pref. Multiple |
Conversion Price |
% Owned |
| Series F1 |
00,000,000 |
00.000000 |
00.00 |
000.00 |
000.00 |
00 |
000.00 |
000 |
| Series F |
00,000,000 |
00.000000 |
00.00 |
000.00 |
000.00 |
00 |
000.00 |
00.00 |
| Series E |
00,000,000 |
00.000000 |
00.00 |
000.00 |
000.00 |
00 |
000.00 |
0.000 |
| Series D |
00,000,000 |
00.000000 |
00.00 |
00.00 |
00.00 |
00 |
00.00 |
00.000 |
| Series C |
0,000,000 |
00.000000 |
00.00 |
00.00 |
00.00 |
00 |
00.00 |
0.000 |
| Series B |
9,048,560 |
$0.000010 |
$0.18 |
$3.07 |
$3.07 |
1x |
$3.07 |
6.28% |
| Series A |
7,119,936 |
$0.000010 |
$0.08 |
$1.26 |
$1.26 |
1x |
$1.26 |
4.94% |
23andMe Competitors (19)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| Pathway Genomics |
Venture Capital-Backed |
San Diego, CA |
000 |
00000 |
00000000000 |
00000 |
| 00000000000 |
Private Equity-Backed |
Hyderabad, India |
00 |
00.000 |
00 000000 |
00.000 |
| 00000 00000000 |
Private Equity-Backed |
Aliso Viejo, CA |
000 |
|
000000&0 |
|
| 00000000000 |
Venture Capital-Backed |
Helsinki, Finland |
00 |
00.000 |
0000000000 0 |
00.000 |
| 000000000 00000000 |
Venture Capital-Backed |
Woburn, MA |
000 |
000.00 |
0000000000 0 |
000.00 |
23andMe Executive Team (38)
| Name |
Title |
Board Seat |
Contact Info |
| Anne Wojcicki |
Co-Founder, Chief Executive Officer & Board Member |
|
|
| Steve Schoch |
Chief Financial Officer |
|
|
| Kathy Hibbs JD |
Chief Legal & Regulatory Officer |
|
|
| Michele Mieuli |
Director, Corporate & Business Development |
|
|
| Erik Karrer Ph.D |
Director of Target Discovery |
|
|
24 Former Executives
23andMe Board Members (8)
To view 23andMe‘s full board member team, request access >>
| Name |
Representing |
Role |
Since |
| Anne Wojcicki |
23andMe |
Co-Founder, Chief Executive Officer & Board Member |
000 0000
|
| Esther Dyson |
Self |
Board Member |
000 0000
|
| Neal Mohan |
23andMe |
Board Member |
000 0000
|
| Patrick Chung JD |
Xfund |
Board Member |
000 0000
|
| Richard Scheller Ph.D |
Self |
Board Member |
000 0000
|
2 Former Board Members
23andMe
Investments
&
Acquisitions (3)
To view 23andMe‘s complete investment and acquisition history, request access >>
| Company Name |
Deal Date |
Deal Type |
Deal Size |
Industry |
Lead Partner |
| 00000 |
13-Dec-2018 |
0000 00000 |
0000 |
Social/Platform Software |
|
| 000000 00 000000 |
20-Jul-2015 |
00000 00000 00 |
0000 |
Other Healthcare Services |
0000 00000000 |
| CureTogether |
10-Jul-2012 |
Merger/Acquisition |
|
Decision/Risk Analysis |
0000 00000000 |